^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pegylated liposomal doxorubicin

    i
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    Apply
    Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (NCT04243616)
    Phase 2
    Medical College of Wisconsin
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/05/2020
    Primary completion :
    07/14/2025
    Completion :
    08/13/2025
    HER-2 • PD-L1 • PGR • PD-L2
    |
    PD-L1 expression • HER-2 negative • PGR positive
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal
    Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) (NCT03907475)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    07/16/2019
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    TMB • CD4 • IL2
    |
    carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)
    A Three-arm Randomized Phase II Study of Dostarlimab Alone or with Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) (NCT06023862)
    Phase 2
    Yonsei University
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    01/22/2024
    Primary completion :
    08/31/2027
    Completion :
    12/31/2029
    MSI • PD-1 • WT1
    |
    Avastin (bevacizumab) • gemcitabine • paclitaxel • doxorubicin hydrochloride • Jemperli (dostarlimab-gxly) • pegylated liposomal doxorubicin
    Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected (EPIK-O) (NCT04729387)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    07/22/2021
    Primary completion :
    04/21/2023
    Completion :
    06/04/2025
    BRCA
    |
    Lynparza (olaparib) • paclitaxel • Piqray (alpelisib) • pegylated liposomal doxorubicin • doxorubicin liposomal
    Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (SL03-OHD-105) (NCT05483933)
    Phase 1
    Shattuck Labs, Inc.
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    08/18/2022
    Primary completion :
    02/07/2025
    Completion :
    02/07/2025
    FOLR1
    |
    FOLR1 expression
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (NCT03203525)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/23/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    PIK3CA • PTEN
    |
    PIK3CA mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • Torisel (temsirolimus) • pegylated liposomal doxorubicin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal
    Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NRG-GY023) (NCT04739800)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/10/2021
    Primary completion :
    01/26/2023
    Completion :
    06/14/2025
    PD-L1 • BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
    Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (NCT02101788)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    02/27/2014
    Primary completion :
    04/04/2019
    Completion :
    10/11/2025
    BRAF
    |
    Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate) • doxorubicin liposomal
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY004) (NCT02446600)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    03/28/2016
    Primary completion :
    02/23/2020
    Completion :
    08/23/2025
    BRCA1 • BRCA2 • BRCA
    |
    BRCA mutation
    |
    Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)
    Pegylated Liposomal Doxorubicin Plus Adebrelimab with or Without Mirabegron in Relapsed Ovarian Cancer (NCT06791460)
    Phase 2/3
    Obstetrics & Gynecology Hospital of Fudan Unive...
    Not yet recruiting
    Last update posted :
    01/24/2025
    Initiation :
    02/15/2025
    Primary completion :
    02/14/2028
    Completion :
    02/14/2030
    CD8
    |
    PD-L1 expression
    |
    pegylated liposomal doxorubicin • Ariely (adebrelimab) • mirabegron
    A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (CA116-001) (NCT05613088)
    Phase 2
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    11/21/2024
    Initiation :
    02/01/2023
    Primary completion :
    06/05/2024
    Completion :
    10/11/2026
    FOLR1
    |
    paclitaxel • pegylated liposomal doxorubicin • topotecan • farletuzumab ecteribulin (MORAb-202)
    Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer (ICON) (NCT03409198)
    Phase 2
    Oslo University Hospital
    Completed
    Last update posted :
    10/14/2024
    Initiation :
    01/21/2018
    Primary completion :
    05/11/2022
    Completion :
    05/11/2022
    HER-2
    |
    HR positive • HER-2 negative
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • pegylated liposomal doxorubicin • doxorubicin liposomal
    Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) (NCT03598270)
    Phase 3
    Grupo Español de Investigación en Cáncer de Ovario
    Completed
    Last update posted :
    08/30/2024
    Initiation :
    11/21/2018
    Primary completion :
    08/05/2024
    Completion :
    08/05/2024
    TMB • BRCA
    |
    PD-L1 expression • BRCA mutation
    |
    Tecentriq (atezolizumab) • carboplatin • gemcitabine • paclitaxel • Zejula (niraparib) • pegylated liposomal doxorubicin • doxorubicin liposomal
    Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (KEYNOTE PN409) (NCT02606305)
    Phase 1/2
    ImmunoGen, Inc.
    Completed
    Last update posted :
    06/14/2024
    Initiation :
    03/02/2016
    Primary completion :
    03/12/2021
    Completion :
    03/12/2021
    FOLR1
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx)
    CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer (NCT05029999)
    Phase 1
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    04/20/2022
    Primary completion :
    04/20/2025
    Completion :
    04/20/2025
    PD-L1
    |
    PD-L1 negative
    |
    pegylated liposomal doxorubicin • CDX-1140 • Mobista (CDX-301)
    Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma. (NCT06393361)
    Phase 2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/01/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    PD-1
    |
    carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)
    Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (LONCA) (NCT05270057)
    Phase 1
    Medical College of Wisconsin
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    01/26/2023
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    BCL2 • BCL6
    |
    MYC rearrangement • BCL6 rearrangement
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)
    A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (ARC-2) (NCT03719326)
    Phase 1
    Arcus Biosciences, Inc.
    Completed
    Last update posted :
    05/24/2024
    Initiation :
    10/15/2018
    Primary completion :
    07/01/2021
    Completion :
    07/02/2021
    HER-2 • ER • PGR
    |
    HER-2 negative • ER negative • PGR negative
    |
    albumin-bound paclitaxel • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928) • doxorubicin liposomal
    Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (COCOS) (NCT02502266)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    05/03/2016
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    BRCA1 • BRCA2 • BRCA • MUC16
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
    Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe) (NCT03971409)
    Phase 2
    Hope Rugo, MD
    Recruiting
    Last update posted :
    05/13/2024
    Initiation :
    07/08/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • PD-L1 • ER • PGR
    |
    HER-2 negative
    |
    Bavencio (avelumab) • Mektovi (binimetinib) • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)
    Combination Therapy for Recurrent Ovarian Cancer (NCT05610735)
    Phase 1/2
    Sham Sunder Kakar
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    05/01/2024
    Primary completion :
    11/01/2026
    Completion :
    11/01/2027
    MUC16
    |
    MUC16 elevation
    |
    pegylated liposomal doxorubicin
    REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (NCT05870748)
    Phase 2/3
    Sutro Biopharma, Inc.
    Recruiting
    Last update posted :
    04/19/2024
    Initiation :
    07/12/2023
    Primary completion :
    09/01/2025
    Completion :
    02/01/2026
    FOLR1
    |
    FOLR1 expression • FOLR1 positive
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)
    9-ING-41 in Patients With Advanced Cancers (Actuate 1801) (NCT03678883)
    Phase 2
    Actuate Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    01/04/2019
    Primary completion :
    11/01/2024
    Completion :
    11/01/2025
    BCL2
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • irinotecan • pegylated liposomal doxorubicin • lomustine • elraglusib (9-ING-41) • doxorubicin liposomal
    Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) (NCT04895358)
    Phase 3
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    03/04/2024
    Initiation :
    06/18/2021
    Primary completion :
    07/21/2028
    Completion :
    07/21/2028
    HER-2 • PD-L1 • ER • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • paclitaxel • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin
    Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative (NCT02456857)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/13/2024
    Initiation :
    01/12/2016
    Primary completion :
    05/24/2023
    Completion :
    05/24/2023
    HER-2 • ER • PGR • VIM
    |
    Avastin (bevacizumab) • everolimus • pegylated liposomal doxorubicin • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal
    Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer (NCT05159193)
    Phase 3
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
    Recruiting
    Last update posted :
    02/02/2024
    Initiation :
    12/20/2021
    Primary completion :
    10/30/2024
    Completion :
    01/31/2028
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • cyclophosphamide • pegylated liposomal doxorubicin • Duomeisu (pegylated liposomal doxorubicin)
    Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer (MIROVA) (NCT04274426)
    Phase 2
    AGO Research GmbH
    Recruiting
    Last update posted :
    01/15/2024
    Initiation :
    10/13/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    BRCA1 • BRCA2 • FOLR1 • MUC16
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • doxorubicin liposomal
    Organoid-based Functional Precision Therapy for Advanced Breast Cancer (ORIENTA) (NCT06102824)
    Phase 2
    Guangdong Provincial People's Hospital
    Recruiting
    Last update posted :
    01/12/2024
    Initiation :
    01/20/2024
    Primary completion :
    06/30/2027
    Completion :
    06/30/2028
    HER-2 • ER • PGR
    |
    HR positive • HER-2 negative • ER positive + PGR positive
    |
    carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Ixempra (ixabepilone) • Lipusu (liposomal paclitaxel) • utidelone IV (UTD1)
    Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY009) (NCT02839707)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    11/08/2023
    Initiation :
    06/23/2017
    Primary completion :
    05/09/2023
    Completion :
    09/21/2024
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal
    Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (NCT02584478)
    Phase 3
    Advenchen Laboratories, LLC
    Active, not recruiting
    Last update posted :
    11/08/2023
    Initiation :
    12/01/2015
    Primary completion :
    10/01/2024
    Completion :
    12/01/2024
    BRCA
    |
    BRCA mutation
    |
    carboplatin • paclitaxel • Focus V (anlotinib) • pegylated liposomal doxorubicin • topotecan
    Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer (ALICE) (NCT03164993)
    Phase 2
    Oslo University Hospital
    Completed
    Last update posted :
    11/01/2023
    Initiation :
    06/01/2017
    Primary completion :
    04/25/2023
    Completion :
    09/30/2023
    HER-2 • PD-L1 • ER • PGR • TMB
    |
    PD-L1 expression • HER-2 negative
    |
    Tecentriq (atezolizumab) • cyclophosphamide • pegylated liposomal doxorubicin • doxorubicin liposomal
    Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women) (NCT00499083)
    Phase 2
    University of Nebraska
    Completed
    Last update posted :
    09/29/2023
    Initiation :
    05/01/2006
    Primary completion :
    07/01/2009
    Completion :
    01/28/2010
    HER-2 • CEACAM5 • PTGS2
    |
    HER-2 overexpression • HER-2 negative • CEACAM5 positive • VEGFA expression
    |
    paclitaxel • tamoxifen • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Soltamox (tamoxifen citrate) • cyclophosphamide intravenous
    Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (NRG-GY029) (NCT05295589)
    Phase 2
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    09/26/2023
    Initiation :
    06/30/2022
    Primary completion :
    03/17/2023
    Completion :
    03/17/2023
    BRCA1 • BRCA2 • HRD • MUC16
    |
    BRCA2 mutation • HRD
    |
    Lynparza (olaparib) • paclitaxel • Aliqopa (copanlisib) • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER (NCT03712956)
    Phase 2
    European Institute of Oncology
    Active, not recruiting
    Last update posted :
    09/21/2023
    Initiation :
    03/25/2016
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    HER-2 • ER
    |
    HER-2 positive • ER positive • HER-2 overexpression • HER-2 negative
    |
    pegylated liposomal doxorubicin • doxorubicin liposomal
    IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (NCT06014528)
    Phase 2
    InxMed (Shanghai) Co., Ltd.
    Recruiting
    Last update posted :
    08/28/2023
    Initiation :
    09/06/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    MUC16
    |
    MUC16 elevation
    |
    pegylated liposomal doxorubicin • ifebemtinib (IN10018)
    Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer (NCT05976932)
    Phase N/A
    Fudan University
    Not yet recruiting
    Last update posted :
    08/04/2023
    Initiation :
    08/01/2023
    Primary completion :
    04/01/2024
    Completion :
    10/01/2024
    TP53
    |
    TP53 mutation
    |
    pegylated liposomal doxorubicin
    Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (CARABELA) (NCT04293393)
    Phase 2
    Spanish Breast Cancer Research Group
    Active, not recruiting
    Last update posted :
    07/19/2023
    Initiation :
    10/02/2020
    Primary completion :
    06/21/2023
    Completion :
    02/28/2033
    HER-2 • PGR
    |
    HR positive • HER-2 negative • PGR negative
    |
    paclitaxel • docetaxel • Verzenio (abemaciclib) • cyclophosphamide • letrozole • pegylated liposomal doxorubicin • goserelin acetate • leuprolide acetate for depot suspension • doxorubicin liposomal
    A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) (NCT02580058)
    Phase 3
    Pfizer
    Completed
    Last update posted :
    07/10/2023
    Initiation :
    12/21/2015
    Primary completion :
    09/19/2018
    Completion :
    07/12/2022
    PD-L1 • CD8
    |
    PD-L1 expression • CD8 positive
    |
    Bavencio (avelumab) • pegylated liposomal doxorubicin • doxorubicin liposomal
    Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer (NCT00258960)
    Phase 2
    Spanish Breast Cancer Research Group
    Completed
    Last update posted :
    04/04/2023
    Initiation :
    02/15/2006
    Primary completion :
    07/01/2008
    Completion :
    07/14/2009
    HER-2
    |
    HER-2 overexpression
    |
    Herceptin (trastuzumab) • cyclophosphamide • pegylated liposomal doxorubicin • cyclophosphamide intravenous